2023. Clinical Response and Safety of Alternating Daily Dosage of Crizotinib due to Side Effects in Advanced NSCLC patient harboring ROS1-rearrangement: A Case Report. Jurnal Respirologi Indonesia. 43, 2 (Apr. 2023), 111–115. DOI:https://doi.org/10.36497/jri.v43i2.201.